Last reviewed · How we verify
Intravenous rhTNK-tPA
rhTNK-tPA is a recombinant thrombolytic agent that dissolves blood clots by converting plasminogen to plasmin, enabling fibrin degradation.
rhTNK-tPA is a recombinant thrombolytic agent that dissolves blood clots by converting plasminogen to plasmin, enabling fibrin degradation. Used for Acute ischemic stroke, Acute myocardial infarction.
At a glance
| Generic name | Intravenous rhTNK-tPA |
|---|---|
| Also known as | Intravenous tenecteplase, Intravenous TNK |
| Sponsor | Xinqiao Hospital of Chongqing |
| Drug class | Thrombolytic agent / Fibrinolytic |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This drug is a genetically engineered tissue plasminogen activator (tPA) variant designed to improve thrombolytic efficacy and safety in acute thrombotic conditions. By enhancing fibrin specificity and reducing systemic plasminogen activation compared to conventional tPA, it aims to achieve faster clot dissolution with potentially lower bleeding risk. The recombinant human TNK-tPA (tenecteplase-like variant) is administered intravenously for rapid thrombus resolution.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction
Common side effects
- Bleeding (intracranial and systemic)
- Reperfusion arrhythmias
- Hypotension
- Allergic reactions
Key clinical trials
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion (PHASE3)
- Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window (PHASE3)
- Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. (PHASE3)
- Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window (PHASE4)
- Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 (PHASE3)
- Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ (PHASE3)
- Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous rhTNK-tPA CI brief — competitive landscape report
- Intravenous rhTNK-tPA updates RSS · CI watch RSS
- Xinqiao Hospital of Chongqing portfolio CI